Researchers of Biogipuzkoa HRI lead a study that relates the use of antipsychotics in dementia with socioeconomic status
en-GBde-DEes-ESfr-FR

Researchers of Biogipuzkoa HRI lead a study that relates the use of antipsychotics in dementia with socioeconomic status

02/07/2024 IOS Press

Disparities by socioeconomic status have been noted in the use of antipsychotics both in the general population and in people with dementia
An analysis of 221,777 individuals over 60 years of age has revealed the greater likelihood of receiving antipsychotics among people with low socioeconomic status
Increasing the offer of non-pharmacological treatments might help reduce inequity in antipsychotic use

July 2, 2024- Donostia-San Sebastian, Spain: A study lead by the Economic Evaluation of Chronic Diseases group of Biogipuzkoa Health Research Institute has revealed the relationship between the use of antipsychotics in dementia and socioeconomic status. This work have been authored by Javier Mar, Uxue Zubiagirre, Igor Larrañaga, Myriam Soto-Gordoa, Lorea Mar-Barrutia, Ana González-Pinto and Oliver Ibarrondo from Biogipuzkoa HRI, Bioaraba HRI, Biosistemak and Mondragon Unibertsitatea.

Antipsychotics are widely used in the elderly due to the high prevalence of neuropsychiatric symptoms and disruptive behaviors associated with dementia. Concern about their inappropriate use has led government reports to warn about their risks and to recommend a reduction in their use for behavioral and psychological symptoms of dementia. Disparities by socioeconomic status have also been noted in their use, and a gradient with educational level has been found in the use of antipsychotics both in the general population and in people with dementia. For a comprehensive analysis of disparities in the indication of antipsychotics, more variables such as sex, age, and somatic and psychiatric comorbidities should be taken into account.

The main findings of this Gipuzkoa population-based study (221,777 individuals over 60 years of age) were the high rates of use of antipsychotics and the greater likelihood of receiving this type of drug among people with low socioeconomic status. The percentage of antipsychotic user rose from 2.9% in high to 6.7% in low socioeconomic status and achieved 39.8% in people with dementia. The explanation for this disparity is that atypical antipsychotics are more often the first-line response to challenging behaviors in dementia in deprived people. Meanwhile, as families are in charge of organizing home care, a higher level of income makes it possible to obtain other support to reduce the distress associated with caregiving and delay the use of antipsychotics.

The main conclusion of the study is that the greater levels of antipsychotic use and institutionalization in people of low socioeconomic indicate a lack of equity in the management of dementia-related neuropsychiatric symptoms. Increasing the offer of non-pharmacological treatments in the public health system might help reduce inequity in antipsychotic use.
These results have been published in the article “Disease Disparities by Socioeconomic Status and Diagnosis of Dementia in the Prescribing of Antipsychotics in a Real-World Data Population Over 60 Years of Age” in “Journal of Alzheimer’s”. An early online version of this paper detailing the findings has been published and is scheduled for publication in the Volume (100), Issue (2), of that journal on July 16, 2024.

DOI: 10.3233/JAD-240004

Authors: Mar, Javiera; b; c; * | Zubiagirre, Uxuea; b | Larrañaga, Igorc | Soto-Gordoa

About the Journal of Alzheimer’s Disease
Now in its 28th year of publication, the Journal of Alzheimer’s Disease (JAD) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment, and psychology of Alzheimer’s disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease, and clinical trial outcomes. JAD has a Journal Impact Factor of 3.4 according to Journal Citation Reports (Clarivate, 2024). The journal is published by IOS Press. www.j-alz.com

About IOS Press
IOS Press is an international scientific, technical, medical (STM) publishing house established in 1987 in Amsterdam. We produce around 100 journals and 70 books annually in a broad range of subject categories, primarily specializing in health and life sciences (including neurosciences, medical informatics, cancer research, and rehabilitation) and computer sciences (including artificial intelligence, data science, and semantic web). In addition, we offer specialized services that support scientific advancement. www.iospress.com.


02/07/2024 IOS Press
Regions: Europe, Netherlands
Keywords: Health, Medical

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...


  • BBC
  • The Times
  • National Geographic
  • The University of Edinburgh
  • University of Cambridge
Copyright 2024 by AlphaGalileo Terms Of Use Privacy Statement